News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Centers for Medicare & Medicaid Services publish preliminary rate for Epigenomics’ colorectal cancer screening test Epi proColon®

PDF Medicare Administrative Contractors determine rate of $192 per test Berlin (Germany) and Germantown, MD (U.S.A.), June 11, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that the Centers for Medicare & Medicaid Services (CMS) published a preliminary rate of $192 per Epi proColon test. Epi proColon is the first and only FDA-approved […]

Read more

Epigenomics AG announces 2018 First Quarter Financial Results

PDF Berlin (Germany) and Germantown, MD (U.S.A.), May 9, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY), or the “Company”, today announced its financial results for the first quarter 2018 ended March 31. Q1/2018 Financial results -Total revenue slightly increased to EUR 309 thousand (Q1 2017: EUR 281 thousand) due to higher product sales (+38%). […]

Read more

Epigenomics AG: Blood test shows promise in the detection of liver cancer

PDF -Results from two clinical studies demonstrate high sensitivity and specificity of mSEPT9 blood test -mSEPT9 test exhibited higher diagnostic accuracy than currently established diagnostic marker -Further independent, prospective clinical study with 440 patients initiated Berlin (Germany) and Germantown, MD (U.S.A.), April 19, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced promising results […]

Read more

Epigenomics AG Reports Results for Financial Year 2017

PDF Berlin (Germany) and Germantown, MD (U.S.A.), March 23, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), or the “Company”, today announced its financial results (according to IFRS) for the year ended December 31, 2017. KEY HIGHLIGHTS Financial Total revenue of EUR 1.9 million EBITDA (before share-based payment expenses) loss of EUR 9.4 […]

Read more

U.S. Senators Capito and Heinrich Introduce Bi-Partisan Colorectal Cancer Detection Bill

PDF Legislation aims to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests Berlin (Germany) and Germantown, MD (U.S.A.), March 8, 2018 – Senators Shelley Moore Capito (R -WV) and Martin Heinrich (D – NM), today introduced the “Colorectal Cancer Detection Act of 2018” to the United States Senate in […]

Read more

Epigenomics AG gets CE-IVD Mark for Lung Cancer Test Epi proLung®

PDF Berlin (Germany) and Germantown, MD (U.S.A.), December 19, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY, “Company”) announced today that it has received CE-IVD mark for its blood-based lung cancer test Epi proLung. Epi proLung is a highly innovative lung cancer test based on the combination of Epigenomics’ proprietary DNA methylation biomarkers. […]

Read more
...